A Feasibility Study of Smoking Cessation Program in Radiation Oncology

NCT ID: NCT00236288

Last Updated: 2007-10-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-10-31
• Study Completion Date: 2007-04-30

Brief Summary

To test the feasibility of an intensive behavioral and pharmacologic tobacco cessation program for radiation oncology patients and their families/companions.

Detailed Description

There is overwhelming evidence to support tobacco use as the number one cause of preventable cancer and cardiovascular death. Smoking is responsible for at least 30% of all cancer deaths and nearly 90% of lung cancer deaths. There is robust phase III randomized data to show improved smoking cessation with both behavioral strategies as well as pharmacologic interventions such as bupropion.

Despite significant evidence showing survival, toxicity and quality of life detriments in cancer patients who continue smoking after diagnosis, roughly one third of cancer patients continue to use tobacco. There is a relative paucity of data regarding smoking cessation programs in cancer patient populations. Several single institution, as well as cooperative group (ECOG), efforts have been published with varying results. However, to date, there are no published reports on the success of pharmacologic smoking cessation interventions in cancer patients.

Patients undergoing definitive/curative radiotherapy often receive daily treatment over the course of three to eight weeks. They are often accompanied and supported daily by family members or companions, many of whom smoke. This represents a huge exposure to the health care system and a unique opportunity for intensive intervention in both cancer patients and their families/companions during their "daily routine" of radiotherapy. To date, there is no published report on intensive tobacco cessation intervention concurrent with radiotherapy in cancer patients and their families or companions.

We propose a feasibility study of an intensive tobacco cessation program to be delivered to radiation oncology patients and/or their family/companions concurrent with planned radiotherapy. This program will feature an intensive behavioral intervention as well as the pharmacologic agent bupropion.

Conditions

Cancer and Tobacco Abuse

Keywords

Cancer treatment and tobacco abuse

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: NONE

Interventions

Bupropion and intensive behavioral therapy

To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Eligibility for Radiotherapy Patients
• age 18 years or older
• receiving three weeks or more of external beam radiotherapy
• report smoking one or more cigarettes in the past 30 days or self-identify as a smoker
• Cancer Stage:
• Stage I-III
• IVa Head and Neck Malignancy is allowed
• Stage I-IV breast, prostate, testis or lymphoma also allowed
• at least one year life expectancy
• have given written informed consent
• KPS 70-100

Eligibility for Family/Companions of Radiotherapy Patients (Note: Family members/companions are eligible for this protocol regardless of whether the index radiotherapy patient is eligible or willing to participate.)

• age 18 years or older
• at least one year life expectancy
• radiotherapy patient is receiving three weeks or more of external beam radiotherapy
• Person is committed to bringing/accompanying the patient to radiotherapy at least three days per week.
• report smoking one or more cigarettes in the past 30 days or self-identify as a smoker
• Family member/companion of patients under radiotherapy treatment for any stage of cancer
• have given written informed consent
• KPS 70-100

Exclusion Criteria

• serious or unstable cardiac, renal, hypertensive, pulmonary, endocrine, or neurologic disorders, as assessed by the study-site physician
• a current diagnosis of major depressive episode or a history of panic disorder, psychosis, bipolar disorder, or eating disorders
• pregnancy or lactation
• any history of allergy/intolerance or adverse reaction to bupropion
• history of seizure disorder, bulimia or anorexia nervosa
• use of an MAOi within 14 days
• current use of another antidepressant
• abrupt discontinuation of alcohol or sedatives
• unwilling/unable to meet with the behavioral interventionalist for 20 minutes, at least 3 days per week during the course of radiotherapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Walther Cancer Institute

OTHER

Sponsor Role: collaborator

Indiana University School of Medicine

OTHER

Sponsor Role: lead

Principal Investigators

Anna McDaniel, DNS, RN, FAAN

Role: PRINCIPAL_INVESTIGATOR

Department of Environments for Health, Indiana University School of Nursing

Locations

Indiana University, Department of Radiation Oncology

Indianapolis, Indiana, United States

Countries

United States

Other Identifiers

Walther Cancer Institute, Inc

Identifier Type: -

Identifier Source: secondary_id

0508-12

Identifier Type: -

Identifier Source: org_study_id